AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧬 AI Cure · starting with cancer

AI to find cure for every human disease — starting with cancer

AI is already finding drug targets, designing molecules and matching patients to trials. AI Cure brings that work to everyone: the evidence on any disease from the world's open research databases, recruiting trials near you, and — for approved researchers and labs — research ideas and an AI assistant that turns questions into testable hypotheses. Every claim cited.

Built on open science: Open Targets·ClinicalTrials.gov·PubMed·PubChem·AlphaFold
📎Every claim citedDatabase IDs on every fact
🌍Every countryThe world by default, or choose yours
🆓Free to exploreNo account for the evidence
🛡️Never called a cureEvidence, with its strength
Understand first

How diseases work

Every disease page starts by explaining what it is, why it happens, and why it is so hard to cure - with animations.

How AI looks for a breakthrough

From a cancer cell to a cited idea

AI Cure follows the path researchers follow - only faster, and in the open.

1 Understand the cancerCancer cells divide without stopping. Medicines work by docking onto the proteins they depend on.
2 Read its genesThousands of genes linked to each cancer, ranked by evidence, with lab CRISPR screens of what the cancer needs.
3 AI connects the evidenceGenes, medicines, safety, trials and papers, joined into ideas a laboratory can test.
4
Every claim citedThe newest papers from the leading journals, live, each with its PubMed ID.
Every cancer

Cancers

36 cancers, each with its genes, every medicine by trial stage, recruiting trials, the newest research and a weekly Breakthrough Tracker.

Most common in India

More cancers

Blood cancers

Children, young people and rare cancers

Beyond cancer

And every other disease

The same evidence and tools work for any human disease — from Alzheimer's to tuberculosis.

Breakthrough Tracker

What changed this year

New phase 3 results, papers in the leading journals and drug label updates, read every week and explained by AI with every source cited.

Breakthroughs around the world

The world is fighting cancer - right now

Every green pulse is a country recruiting cancer patients into trials today. Beside it, the newest phase 3 results, as they are posted.

109countries recruiting
102phase 3 results this year
83papers in leading journals
Triple-negative breast carcinomaStudy of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)NCT03036488 · results posted 2026-10-22 · Merck Sharp & Dohme LLC Hodgkins lymphomaBrentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLNCT04404283 · results posted 2026-10-21 · Seagen, a wholly owned subsidiary of Pf… Hodgkins lymphomaNKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaNCT05664217 · results posted 2026-10-16 · Nektar Therapeutics Small cell lung carcinomaA Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerNCT03194893 · results posted 2026-10-09 · Hoffmann-La Roche Small cell lung carcinomaA Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)NCT03456063 · results posted 2026-10-09 · Hoffmann-La Roche Small cell lung carcinomaTesting the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung CancerNCT04214262 · results posted 2026-10-06 · National Cancer Institute (NCI) MesotheliomaDuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaNCT04334759 · results posted 2026-10-01 · PrECOG, LLC. Breast cancerA Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582 · results posted 2026-09-29 · Seagen, a wholly owned subsidiary of Pf… Urinary bladder cancerA Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerNCT06331299 · results posted 2026-09-28 · UroGen Pharma Ltd. Urinary bladder cancerA Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following CystectomyNCT04660344 · results posted 2026-09-28 · Hoffmann-La Roche B-cell chronic lymphocytic leukemiaA Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)NCT05023980 · results posted 2026-09-25 · Loxo Oncology, Inc. Ovarian cancerRelacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerNCT05257408 · results posted 2026-09-25 · Corcept Therapeutics Renal cell carcinomaA Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadNCT04810078 · results posted 2026-09-22 · Bristol-Myers Squibb Small cell lung carcinomaDouble Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCNCT02273375 · results posted 2026-09-14 · Canadian Cancer Trials Group MelanomaPercutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular MelanomaNCT02678572 · results posted 2026-09-10 · Delcath Systems Inc. Prostate cancerCapivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyNCT04493853 · results posted 2026-09-10 · AstraZeneca Hepatocellular carcinomaSafety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)NCT04246177 · results posted 2026-09-03 · Merck Sharp & Dohme LLC Cervical cancerImpact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With RadiotherapyNCT01520701 · results posted 2026-09-01 · Centre Francois Baclesse B-cell chronic lymphocytic leukemiaAcalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia PatientsNCT04008706 · results posted 2026-09-01 · AstraZeneca MelanomaA Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaNCT05625399 · results posted 2026-08-26 · Bristol-Myers Squibb

Sources: ClinicalTrials.gov (recruiting trials and posted results), PubMed (leading journals). Refreshed every week.

For patients and families

What you can do

Only facts from public evidence, each with its source. Free, for everyone.

For researchers, doctors and labs

Find the next breakthrough with us

Research ideas are not proven, so they are shared with the people who can test them. Approved researchers and labs get the full research section, free.

🔭Discovery EngineSynthetic-lethal weak points, cancer dependencies from CRISPR screens, repurposing and combinations of approved medicines, and targets no medicine reaches yet.
💡Idea Ledger · 503 ideasEvery idea graded, with evidence for and against, a prediction that could prove it wrong and the cheapest experiment. Labs claim ideas and report results.
🔬Hypothesis Lab and Molecule CheckTurn a research question into a testable hypothesis from the newest papers; check any compound's drug-likeness.
Synthetic lethality, explainedHealthy cells stand on two genes. A cancer that has lost one depends on the other - so a medicine that blocks it can bring the cancer down and spare healthy cells. Approved PARP inhibitors for BRCA-mutated cancers work this way.
Repurposing, explainedA medicine approved for one disease may also fit a protein a cancer needs. Its safety in people is already known, so testing a new use can take years less than a new molecule.
🤝 Apply for research access
How it works

Evidence first, then AI

Open evidenceFacts come only from public research databases, each with its ID, so anyone can check them.
AI reasons over itThe AI reads only that evidence and explains where the science stands, citing every claim.
You decide, with expertsPatients take the facts and questions to their doctor; approved researchers take the ideas to the lab.
Honest about AI

Where AI really stands

The first AI-designed medicines are in human trials, and none has yet completed approval.

🚀

What AI does today

  • Reads biology at scale and ranks the genes behind a disease
  • Predicts protein structures (AlphaFold)
  • Designs new molecules and finds new uses for old medicines
  • Matches patients to trials
🔬

What it cannot skip

  • Laboratory work to prove an idea
  • Careful clinical trials in people
  • Review by regulators
  • So AI Cure never calls anything a cure — it shows the evidence and how strong it is
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy